Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Elrexfio Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
Historically, the observed expansion was driven by the shortcomings of traditional chemotherapy, an increase in lymphoma cases, significant progress in monoclonal antibody research, enhanced methods for cancer diagnosis, and a rising number of approved medications for oncology.
The projected growth during the forecast period can be attributed to the escalating adoption of immunotherapies, the expansion into additional indications, advancements in precision oncology, increasing investment in biologics, and improved patient survival outcomes.
Major trends anticipated in the forecast period include the uptake of bispecific antibodies, the broadening of immuno-oncology therapies, their rising use in refractory lymphomas, a strong preference for targeted cancer treatments, and progress in T-cell engaging therapies.
Get A Free Sample Report With In-Depth Market Insights:
Elrexfio Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing incidence of multiple myeloma is anticipated to boost the expansion of the elrexfio market in the coming years. Multiple myeloma, a cancer originating in plasma cells—a type of white blood cell located in the bone marrow—results in the uncontrolled proliferation and buildup of these cells, leading to harm in bones, kidneys, and various other organs. Factors such as a progressively older demographic, enhanced understanding, developments in diagnostic methods, and improved access to healthcare contributing to earlier detection, are reasons behind the growing occurrence of multiple myeloma. Elrexfio (elranatamab) functions as a monoclonal antibody, addressing multiple myeloma by specifically targeting and attaching to the BCMA (B-cell maturation antigen) protein found on myeloma cell surfaces, thereby stimulating the immune system to eliminate these cancerous cells. As an illustration, in February 2023, Cancer Research UK, a UK-based research organization, reported that the projected annual new myeloma cases in the UK are set to climb from approximately 6,800 cases between 2023-2025 to roughly 8,300 between 2038 and 2040. Consequently, the rising prevalence of multiple myeloma is fueling the growth of the elrexfio market.
Elrexfio Market Segment Analysis And Revenue Potential
The elrexfio market covered in this report is segmented –
1) By Indication: Multiple Myeloma, Other Hematologic Cancers
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Research Institutions, Other End Users
#Elrexfio Market Growth Trends: What’s Shaping The Future Outlook?
A significant trend within the elrexfio market is the development of advanced therapies, such as B-cell maturation antigen-targeted therapy, aimed at boosting treatment efficacy for cancer and autoimmune diseases. B-cell maturation antigen (BCMA) targeted therapy is a type of cancer treatment specifically designed to target the BCMA protein present on the surface of malignant plasma cells, including those involved in multiple myeloma. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, obtained approval from the U.S. Food and Drug Administration (FDA) for elranatamab-bcmm (Elrexfio). Elranatamab-bcmm (Elrexfio) functions as a bispecific T-cell engager therapy that targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells, thereby helping to activate the immune system to fight relapsed or refractory multiple myeloma in adults who have undergone multiple lines of prior treatment.
Elrexfio Market Key Players Shaping Industry Direction
Major companies operating in the elrexfio market are Pfizer Inc.
View The Full Elrexfio Market Report:
Elrexfio Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the elrexfio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elrexfio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
